Literature DB >> 35802845

Hypersensitivity reactions with tixagevimab/cilgavimab (Evusheld).

.   

Abstract

Entities:  

Keywords:  COVID-19; Evusheld ; adverse effects; cilgavimab ; safety; tixagevimab

Mesh：

Substances：

Year:  2022        PMID： 35802845

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN： 0025-732X            Impact factor:   1.677


× No keyword cloud information.
  1 in total

Review 1.  A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment.

Authors:  Daniele Focosi; Arturo Casadevall
Journal:  Viruses       Date:  2022-09-09       Impact factor: 5.818
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.